Cell Therapeutics to Resume Trading
Luke Timmerman2/17/09
Cell Therapeutics, the Seattle-based biotech company, said today that Italian securities regulators will allow trading in its shares to resume in Italy on Feb. 18 after it issued a statement detailing its finances. This means the company expects (NASDAQ: CTIC) to re-start trading in the U.S. on Feb. 18 as well. The company has run dangerously low on cash, with only enough money to run through February, as we described last week. Cell Therapeutics’ last traded in the U.S. at 8 cents.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
